Abstract
Onychomycosis is a common nail infection for which treatment options are limited, and no new treatment have been introduced for over 10 years. While patients might prefer a topical therapy, efficacy with ciclopirox and amorolfine lacquers has been disappointing especially in moderate to severe disease. Efinaconazole 10% solution is a new triazole antifungal, specifically developed for the topical treatment of onychomycosis. Its physicochemical properties, antifungal activity and formulation are all important aspects of the development program and are reviewed here. Efinaconazole 10% solution may provide the first viable alternative to oral therapy for onychomycosis. Mycologic cure rates are comparable to those seen with oral itraconazole, and greater than reported with ciclopirox lacquer.
Financial & competing interests disclosure
The author was supported by Medicis, a division of Valeant Pharmaceuticals. BM Elewski was a consultant to Medicis, a division of Valeant Pharmaceuticals and an investigator in the efinaconazole clinical study. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Writing assistance was utilized in the production of this manuscript. The author would like to thank Brian Bulley, MSc (Inergy Limited, UK) for assistance with the preparation of the manuscript. Medicis, a division of Valeant Pharmaceuticals, funded Inergy’s activities pertaining to this manuscript.